secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALISADE BIO, INC. (PALI)
CIK:        0001357459
Form:       8-K
Filed at:   2024-04-10T23:59:59+00:00
Accession:  0001493152-24-014253
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Palisade Bio details PALI-2108 development for ulcerative colitis at IBD conference
--------------------------------------------------------------------------------

- PALI-2108 is a colon-specific PDE4 inhibitor prodrug for moderate-to-severe ulcerative colitis.
- Phase 1 clinical study planned to begin before year-end 2024.
- Development supported by $500,000 research agreement with Giiant from the Crohn's & Colitis Foundation.
- Presentation given at IBD Innovate in Cambridge, MA on April 9-10, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357459/000149315224014253/0001493152-24-014253-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357459/000149315224014253/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-014253

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer